Results 131 to 140 of about 311,881 (293)
Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy
Advanced Science, EarlyView.Cancer immunotherapy faces challenges in predicting treatment responses and understanding resistance mechanisms. Artificial intelligence (AI) and machine learning (ML) offer powerful solutions for cancer immunotherapy in patient stratification, biomarker discovery, treatment strategy optimization, and foundation model development.
Xinchao Wu +4 more
wiley +1 more source
Enhancing CAR‐T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF‐Mediated Angiogenesis
Advanced Science, EarlyView.This study reveals that CAR‐T cells in solid tumors produce CCL5, which paradoxically induces VEGF and angiogenesis to promote tumor growth. Blocking CCL5/VEGF signaling—through gene knockout, or the CCR5 inhibitor maraviroc—significantly enhances the antitumor efficacy of CAR‑T therapy (the diagram was created in Biorender).
Shishuo Sun +15 more
wiley +1 more source
Advanced Science, EarlyView.Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang +6 more
wiley +1 more source
Advanced Science, EarlyView.This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård +19 more
wiley +1 more source
Advanced Science, EarlyView.ARHGEF3 is broadly downregulated across human cancers and correlates with patient prognosis. Tumor‐intrinsic ARHGEF3 activates the RHOA–ROCK–PTEN cascade to inhibit AKT signaling, thereby promoting chemokine‐driven T‐cell infiltration and relieving lipid‐mediated myeloid immunosuppression.
Yue Li +8 more
wiley +1 more source
Advanced Science, EarlyView.ABSTRACT Despite the transformative impact of cancer immunotherapies such as immune checkpoint blockade, durable clinical responses remain limited. Increasing evidence indicates that antitumor immunity is governed not only by the tumor microenvironment, but also by systemic immune regulation mediated by peripheral immune organs. Among these, the spleen
Yuehua Liu, Xiaoqian Nie, Xiaofei Gao
wiley +1 more source
Trained Memory of Uterine Macrophages Improves Subsequent Pregnancy Outcomes
Advanced Science, EarlyView.This study identifies that pregnancy imprints a durable, pregnancy‐specific form of trained immune memory in uterine macrophages, marked by the emergence of LILRB3+/PIR‐B+ cells that expand across gestations, acquire a tolerogenic and metabolically rewired phenotype, and actively protect against inflammatory pregnancy loss in mice.
Jing Wang +8 more
wiley +1 more source
Advanced Science, EarlyView.ABSTRACT Tumor immune escape is a major barrier to durable cancer immunotherapy, as advanced malignancies create a tumor microenvironment (TME) that preferentially exhausts and disables T cell responses. While most approved cell therapies are T cell‐based, this limitation motivates the exploration of an alternative effector cell platform.
Tereza Kochs +4 more
wiley +1 more source
Advanced Intelligent Discovery, EarlyView.scTIGER2.0 is a deep‐learning framework that infers gene regulatory networks from single‐cell RNA sequencing data. By integrating correlation, pseudotime ordering, deep learning and bootstrap‐based significance testing, it reduces false positives and reveals directional gene interactions.
Nishi Gupta +3 more
wiley +1 more source
American Journal of Hematology, EarlyView.ABSTRACT In a large multicenter real‐world cohort, we aimed to evaluate outcomes of FLAG‐Ida salvage therapy for relapsed/refractory (R/R) acute myeloid leukemia (AML) and validated the SALFLAGE prognostic score. We analyzed 1079 adults with R/R AML treated across 112 PETHEMA institutions over 26 years (1998–2024), including patients with primary ...
Gaspar Aspas Requena +49 more
wiley +1 more source